BLOG

The Making of a Gene Therapy for an Ultra-Rare Disease

While the since renamed company Sio Gene Therapies in-licensed one program in Parkinson’s disease, it also in-licensed a pair of gene therapy programs from the University of Massachusetts in GM1 gangliosidosis and Tay-Sachs/Sandhoff disease with the GM1 program being Sio’s lead candidate.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}